Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 28%
Buy 56%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is making significant strides in their pipeline with the development of next-generation ADCs targeting Folate receptor alpha (FRα), as well as new drugs targeting IRAK4 and CD19 receptors in immunology and neuroscience. With strong sales growth for their existing immunology drugs, such as Rinvoq and Humira, and the recent acquisition of Allergan's aesthetic products, AbbVie is poised for long-term success. Additionally, the company has a diverse range of potential catalysts in upcoming years, including multiple Phase 3 data readouts and FDA decisions.

Bears say

AbbVie is performing well in the current quarter with total net revenues and adjusted EPS exceeding expectations, driven by key drivers such as Skyrizi, Rinvoq, Botox, Ubrelvy, Vraylar, and Venclexta. However, concerns include potential competition and pricing risks for Skyrizi and Rinvoq, as well as potential future pricing headwinds and clinical risks in the immunology field. Additionally, AbbVie's low tax rate and potential changes in tariffs or taxes could impact its performance as a company.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 56% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $256.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $256.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.